MSI1 and central nervous system cancer: In this study we combined the tumor cell specific markers in a double immunofluorescence protocol with the following panel of stem cell markers: CD133 [4, 13–18], Nestin [18–24], Musashi-1 [18, 25–28], Sox-2 [18, 29–32] and Bmi-1 [18, 29, 32, 33], to characterize the phenotype of migrating glioma cells.